Elias Jabbour, MD, a professor within the Division of Leukemia, Division of Most cancers Medication, at The College of Texas MD Anderson Most cancers Heart in Houston, gives an outline of the importance of the FDA approval of ponatinib (Iclusig) plus chemotherapy for the therapy of grownup sufferers with newly recognized Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Transcription:
0:09 | On March 19, the FDA granted approval for ponatinib as a first-line possibility for Ph+ ALL. That is the primary time ever the place the FDA permitted a drug for first-line ALL therapy with chemotherapy. Not solely [is it] the primary time, however it’s the first time within the historical past of acute leukemia the place the approval was primarily based on [minimal residual disease (MRD)] evaluation on the finish of induction. That is the primary examine in Ph+ ALL the place the FDA granted approval primarily based on assembly the first finish level of MRD-negative [complete response (CR)], and now, we’ve a first-line tyrosine kinase inhibitor [TKI] permitted.
0:48 | The obvious factor is you want a drug that may present a speedy medical profit with an final long-term enchancment. There’s loads of proof suggesting that if we will eradicate minimal illness early on, that correlates with the long-term survival profit…There was a meta-analysis revealed that confirmed that amongst 13,000 sufferers, those that are MRD-negative did a lot better than [patients who were] MRD-positive and due to this fact, we all know it does assist.
1:20 | We at MD Anderson have proven that if one has 3 months [of] MRD negativity, sufferers have a greater consequence. With this proof, we did negotiate with the company about contemplating early MRD negativity as a surrogacy for long-term consequence profit and as such for approval. After assessing the entire proof, the FDA agreed to contemplate MRD-negative CR as the first finish level. Which means the affected person must have, on the finish of induction or 12 weeks, a CR sustained for a month at the least, and have 10-4 MRD negativity.
